author-photo

Alex P. Hoyle

University of Salford

8

Papers

687

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial

2020
Show All
- Source
- Cite
- Save
Citations (7)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992–2003

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (114)
844ODocetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
850PDBenefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1|RT comparison”

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

2018 The Lancet
Show All
- Source
- Cite
- Save
Citations (482)